Advance Publication

Experimental Animals

Received: 2021.9.3

Accepted: 2021.11.1

J-STAGE Advance Published Date: 2021.11.25

**Anti-inflammatory effect of HGF responses to oral traumatic ulcers
using an HGF-Tg mouse model**

Research of HGF using HGF-Tg mouse model

Xinhong Wang^a, Liting Yan^{a,b}, Yinghua Tang^a, Xiaoxi He^a, Xiaomin Zhao^a, Weijia Liu^a, Zhicong Wu^a, Gang Luo^a

^aDepartment of oral medicine, Affiliated Stomatology Hospital of Guangzhou Medical University, Guangzhou Key Laboratory of Basic and Applied Research in oral Regenerative Medicine, Guangzhou, Guangdong, 510182, China

^bWuxi stomatology hospital, Wuxi, Jiangsu, 214001, China

Correspondence: Gang Luo, Stomatology Hospital of Guangzhou Medical University, Guangzhou, Guangdong, P.R. China, 510140, E-Mail: gangluo2020@163.com

Wang XH and Yan LT contributed equally to this paper.

**Anti-inflammatory effect of HGF responses to oral traumatic ulcers
using an HGF-Tg mouse model**

Abstract

Hepatocyte growth factor (HGF) has been implicated in inhibiting diverse types of inflammation. Oral traumatic ulceration (OTU) is a common disease of the oral mucosa, and inflammation is the main process for ulcer healing. This study aimed to explore the expression of HGF in oral ulcers and its role in ulcer inflammation. The saliva of 14 recurrent aphthous stomatitis (RAS) patients, 18 OTU patients and 17 healthy controls was collected. Traumatic ulcers of the left mucosa were observed in 42 wild-type (WT) and 42 HGF-overexpressing transgenic (HGF-Tg) mice. Histological scores, inflammatory cell expression and serum cytokine expression were measured and analyzed on the 5th day. The HGF protein level in ulcer-affected human saliva was 9.3-fold higher than that in healthy saliva. The HGF protein levels in RAS and OTU saliva were 14- and 5.7-fold higher, respectively, than those in healthy saliva. Traumatic ulcers enhanced HGF expression in ulcer-affected oral mucosa and

in the blood of C57BL/6 mice by 1.21- and 1.40-fold, respectively. In HGF-Tg mouse traumatic ulcers, HGF expression was 1.34-fold higher than that in wild-type mice. HGF-Tg mice had lower weight loss, less ulcer area and lower histopathology scores than WT mice. The results from immunohistochemistry, flow cytometry and serum cytokine analysis showed that HGF-Tg animals presented fewer Ly6G-positive neutrophils and higher levels of circulating inflammatory cytokines. HGF overexpression alleviated weight loss, ulcer area and inflammation, suggesting the role of HGF in promoting the healing of oral ulcers.

Key words: HGF, oral ulcer, cytokine, inflammation

Anti-inflammatory effect of HGF responses to oral traumatic ulcers using an HGF-Tg mouse model

Introduction

Traumatic ulcers of the oral mucosa are relatively frequent and may be induced by many underlying etiologic factors [1,2,3]. Oral traumatic ulcers feature discontinuity of the epithelium and inflammatory granulation tissue under damaged epithelium. Healing happens in a spontaneous manner that may vary from 1 to 2 weeks if the source of the trauma is removed. Chronic nonhealing ulcers are trapped in a prolonged inflammatory cycle and fail to proceed to the normal progression of healing [4]. The infiltration of inflammatory cells following the level of inflammatory cytokines is essential for the tissue repair and wound healing of ulcers [5,6].

The HGF protein is essential for embryonic development, which is mainly expressed by mesenchymal cells [7]. It is abnormally expressed in various cancers and plays a role in the regulation of the biological behavior of cancer [8]. Moreover, HGF expression increases following a variety of injuries and autoimmune inflammatory diseases. Level of HGF are increased in epithelium, mesenchymal and endothelium cells in injured tissues, so HGF is essential for self-repair after injuries [7,8,9]. It has been postulated that cells of the immune system contribute to regulating the expression of HGF and c-Met following injury and inflammation [10,11]. HGF has been reported to inhibit the secretion of inflammatory cytokines and promote the secretion of anti-inflammatory cytokines [12,13,14].

In recent years, the application of HGF has been considered a new potential clinical drug in ulcer healing based on preclinical and clinical studies. The therapeutic effect of HGF has been examined in acute or chronic inflammation/fibrosis models [15,16]. HGF has been reported to modulate the inflammatory environment and enhance wound healing and regeneration in animal models of inflammation-associated diseases, including a skin inflammation model [17], multiple sclerosis model [18], pulmonary artery hypertension model [19] and bronchiolitis obliterans model [20]. HGF can mediate wound healing by accelerating the regeneration of epithelial cells [21,22] and by maintaining normal immune function [17]. Clinical

data have shown that HGF gene therapy can significantly decrease the size of ulcers in patients with critical limb ischemia [23,24].

As described above, HGF promotes wound healing by inhibiting inflammation in injured tissues. In oral mucosal tissues, elevated expression of HGF can increase oral mucosal fibroblast (OMF) proliferation in vitro, which is required for the wound healing properties of OMF [25]. Based on the existing knowledge, we hypothesized that HGF will alleviate inflammation and promote healing of oral ulcers in vivo. However, the effect of HGF on ulcer immune cells during oral traumatic ulcers is still a mystery.

In this study, we aimed to analyze the expression pattern of HGF in traumatic ulcer-affected oral mucosa tissue and tested the effects of HGF on ulcer area, inflammatory cells and cytokine expression in traumatic injury of the oral mucosa. Because of the short biological half-life of internal HGF protein, intravenous medicine delivery cannot ensure the effective function of HGF in traumatized tissues; thus, we established HGF-overexpressing transgenic (HGF-Tg) mice whose HGF expression level was higher than that of wild-type (WT) mice [26].

Methodology

Collection of human saliva

Human saliva (5-10 ml) was obtained from healthy controls (n=17), patients with recurrent aphthous stomatitis (RAS) (n=14) and patients with oral traumatic ulceration (OTU) (n=18) without any systemic disease. The clinical characteristics of the patients and controls are summarized in supplementary Table 1. Human saliva was used to analyze HGF protein expression by ELISA.

Animals

Wild-type C57BL/6J (WT) and HGF-overexpressing transgenic C57BL/6J (HGF-Tg) mice were used in this study. HGF-Tg mice were generated according to a previous report [26]. Briefly, the vector pRP[Exp]-CAG>mHgf[ORF045947] was injected into fertilized oocytes (C57BL/6J background) by pronuclear injection (Cyagen Biosciences) and HGF-overexpression transgenic mice (HGF-Tg) were

established and verified by the following primers: HGF (forward): 5'-TCTAGAGCCTCTGTAAACCATGTTC-3', HGF (reverse): 3'-CCTGATACACCTGTTGGCACAC T-5'. control Rgs (forward): 5'-CAACCACTTACAA GAGACCCGTA -3', control Rgs (reverse); 3'-GAGCCCTTAGAAATAACGTTC ACC-5'. In total, 42 WT and 42 HGF-Tg mice aged 8–10 weeks were used in this experiment. The mice were kept under 12-hour/12-hour light/dark cycles with free access to food and water in the Central Animal Laboratory of Guangzhou Medical University.

Oral mucosa traumatic ulcer protocol

Traumatic ulcers of the oral mucosa were generated using the method described by Cavalcante in 2011[5]. Briefly, the mice were anesthetized with 0.1–0.2 ml of pentobarbital sodium (0.1%) via intraperitoneal injection, and the oral mucosa was sterilized using 0.12% chlorhexidine gluconate. Ulceration was performed on the left oral mucosa using a number 15 scalpel blade; a 3-mm marker was used for standardization. The protocol was performed by the same investigator (Xiaoxi He) for standardization. We chose the 5th day as the sacrifice day because the mice lost weight during the first 5 days [5].

Clinical and histological evaluation of traumatic ulcer

The mice were weighed from day zero to the sacrifice day (5th day), and weight loss= (final weight-initial weight). The larger (L) and minor (M) diameters of the ulcer were measured on the 3rd and 5th days. The area of the ulcer was calculated (area= $\pi \times L \times M$). All measurements were performed by Xiaoxi He. The mucosa containing the ulcer was collected and fixed in 10% formalin after the mice were sacrificed. After being embedded in paraffin, the tissues were sectioned into 4- μ m slices that were then mounted on slides and stained with hematoxylin and eosin (HE) for inflammation score evaluation (from 0 to 4 according to published evaluation criteria) [2]. Blood collection and sample collection were performed separately on the 5th day.

ELISA analysis for protein expression

ELISA was used to analyze the protein levels in human OTU saliva, mouse oral mucosa tissue protein extract and mouse serum. Mouse mucosal ulcer tissues were stored at -80°C for use. Frozen mucosal ulcer tissues were solubilized in lysis buffer at 4°C for 20 min and then centrifuged at 4°C for 20 min (1500×g). The supernatant was collected, and the protein contents were detected by Coomassie Plus Protein Lysate Reagent (Pierce, Rockford, IL, United States). Mouse serum was separated by centrifugation (2000 rpm, 5 min). The protein level of HGF was measured in mice (RayBio® Mouse HGF ELISA Kit, Norcross, U.S. A) and human (RayBio® Human HGF ELISA Kit, Norcross, U.S. A) HGF ELISA kits, as instructed by the manufacturer's protocol.

Serum cytokine analysis

Serum cytokines were tested in duplicate alongside a standard with the Mouse Cytokine Array Q5 (RayBio, QAM-CYT-5) according to the manufacturer's instructions. The fluorescent signal intensity was measured using an InnoScan 300 Microarray Scanner (Parc d'Activités Activestrel, 31390 Carbonne, France) at a wavelength of 532 nm and a resolution of 10 µm. All results were analyzed using Q-Analyzer software for QAM-cyt-5. Healthy wild-type mice (n=3), WT mice with ulcers (n=5) and HGF-Tg mice with ulcers (n=8) were included in this analysis.

Flow cytometry analysis

Cell suspensions were prepared from mouse ulcer tissues and immune cells from WT and HGF-Tg mouse blood for flow cytometry analysis. Cells were washed and resuspended in PBS (1×10⁶/ml), and cells were stained for 30 min at 4°C with the following antibodies: CD45-APC-Cy7 (BD, Lot: 7096638), CD4-PE (BD, Lot: 7138675), CD8-FITC (Invitrogen, Lot: 4329219), CD11b-Percy5.5 (BD, Lot: 7066558), Ly6G-FITC (BD, Lot: 7052879), CD19(BD, Lot:550992) and CD3 (BioLegend, Lot: 10203). The cells were sorted by flow cytometry (BD FACS Aria III), and the data were analyzed using FlowJo software (BD FACS Diva software).

Immunohistochemical staining for CD45 and Ly6G

Slides bearing 4-µm tissue slices were deparaffinized and rehydrated and then processed according to a standard immunohistochemical staining manual. Briefly, endogenous peroxidase was blocked with 3% H₂O₂, and then, the samples were

incubated for 1 hour at room temperature with primary antibodies against CD45 (Lot: 7096638, BD, USA, dilution 1:100) and Ly6G (bs-2576R, Bioss, USA, dilution 1:100), after which they were incubated with HRP secondary antibodies and substrate. The score of the Ly6G-positive cells was calculated according to Li with a minor change [27]: the average positive cell ratios were photographed and counted in 3–5 fields (400X) and then scored as follows: 0: 0% positive cells; 1: 1–33% positive cells; 2: 34–66% positive cells; and 3: 67–100% positive cells. CD45 was qualified by the average positive cell number that was counted in 3–5 fields (400X).

Statistical analysis

SPSS 19.0 (IBM, USA) was used to calculate the statistical significance between groups. The unpaired t-test, Mann-Whitney U test and ANOVA were used to compare the differences between groups. Quantitative data are expressed as the means $\pm$ standard deviation (mean $\pm$ SD). GraphPad Prism 6 software (La Jolla, CA, USA) was used to plot the comparison of means, and $p \leq 0.05$ was considered a statistically significant difference.

Results

Oral traumatic ulcers amplify HGF expression in oral mucosa.

First, we examined the expression of HGF in human saliva of 14 RAS patients, 18 OTU patients and 17 healthy individuals. The HGF protein level in ulcer-affected human saliva was 9.3-fold higher compared with healthy saliva. The HGF protein levels in RAS and OTU saliva were 14 and 5.7-fold higher separately compared with that in healthy saliva. The HGF protein level in RAS-affected human saliva was 2.5-fold higher compared with that in OTU patients (Figure 1A). The HGF protein level in the normal oral mucosa of HGF-Tg mice was 1.38-fold higher than that in WT mice (Figure 1B). The HGF protein level in the oral ulcers of HGF-Tg mice was 1.34-fold higher than that in WT mice (Figure 1B). The HGF protein level in oral ulcers of WT mice was 1.21-fold higher than that in healthy oral mucosa (Figure 1B). At the same time, HGF protein expression was 1.1-fold higher in oral ulcers of HGF-Tg mice than in HGF-Tg healthy mucosa (Figure 1B). The serum HGF protein level in HGF-Tg mice was 1.33-fold higher than the serum HGF protein level in WT mice

(Figure 1C). The serum HGF protein level of the WT oral ulcer mice was 1.40-fold higher than that of the WT healthy mice (Figure 1C). The serum HGF protein level in oral ulcers of HGF-Tg mice was 1.11-fold higher than that in WT mice (Figure 1C). At the same time, serum HGF protein expression was 1.16-fold higher in oral ulcers of HGF-Tg mice than in HGF-Tg healthy mucosa (Figure 1C).

High HGF expression alleviates weight loss and the ulcer area of oral ulcers.

Area analysis of the ulcer showed that the ulcer area of all the groups showed a decrease on the 3rd and 5th days compared with day zero, and HGF-Tg mice showed a significantly lower ulcer area on the 3rd and 5th days compared with the WT group (Figures 1D, 1E). All mice were alive on the sacrifice day, and there was a significant decrease in weight variation from the 1st to 4th day compared with day zero in both groups. HGF-Tg mice showed weight gain, and WT mice were close to the baseline weight value on the 5th day. Although the WT mice showed more weight loss than the HGF-Tg mice from the 1st to 5th day, only the 1st day was significantly different (Figure 1F).

Higher expression of HGF alleviates inflammation of oral ulcers.

Microscopic analysis of the cheek trauma of HGF-Tg mice on the 5th day revealed the presence of less ulceration associated with moderate fibrosis and chronic inflammatory processes. In the WT ulcer mice, we found a persistence of ulcers and mixed inflammatory infiltrates (neutrophils and mononuclear cells). The HGF-Tg group exhibited less ulceration and inflammation than the WT group (Figures 2A, 2B).

To characterize the impact of HGF on oral mucosal ulcer tissue and circulating inflammatory cells, we performed flow cytometry analysis 5 days after oral traumatic ulcer induction. Blood T cells were gated by CD3⁺/CD8⁺ or CD4⁺, B cells were gated by CD19⁺, and neutrophils were gated by CD11b⁺/Ly6G⁺. The T cells of the ulcer tissues were gated by CD45⁺/CD8⁺ or CD4⁺, neutrophils were gated by CD45⁺/CD11b⁺/Ly6G⁺, and B cells were gated by CD19⁺. We found that fewer neutrophils (Figure 3A, 3B) were visualized in the blood of HGF-Tg mice than in the blood of WT mice. In contrast, more T cells were visualized in the blood of HGF-Tg mice than in the blood of WT mice (Figures 3E, 3F). There was no significant

difference in terms of blood B cells between HGF-Tg and WT mice (Figures 3C, 3D). Flow cytometry revealed that there was no significant difference in the CD4⁺/CD8⁺ ratio between the groups (Figures 3G, 3H). In this study, we also detected inflammatory cells in the oral ulcer tissue by flow cytometry. Fewer neutrophils were also found in the ulcer tissue of HGF-Tg mice than in that of WT mice (Figure 4). However, CD4⁺T, CD8⁺T and B cells could not be detected in ulcer tissue by flow cytometry because the number of cells was less than the lowest detection limit.

Similarly, we investigated Ly6G and CD45 expression in ulcer tissues using immunohistochemical staining. There was more Ly6G-positive neutrophil infiltration in the WT mice, and it was significantly lower in the HGF-Tg group (Figures 2E, 2F). The number of CD45-positive cells showed no difference between HGF-Tg ulcers and WT ulcers (Figures 2C, 2D).

We further analyzed blood inflammatory cytokines using a RayBiotech antibody array experiment. In this assay, compared with the WT ulcer group, we detected 38 greater and 2 lesser (MIP-1 alpha, fractalkine) amounts of serum cytokine production in the ulcers of the HGF-Tg mice (supplementary Table 2). Eotaxin, MIP-1 gamma, BLC, Eotaxin-2, RANTES, Lix and IL-3 were upregulated by more than 1.4-fold in the ulcers of the HGF-Tg mice compared to in the ulcers of the WT mice (supplementary Table 2, Figure 5). When comparing the HGF-Tg group with the control group, eotaxin, MIP-1 gamma, BLC, MCSF, RANTES, Lix and IL-3 showed more than 1.5-fold expression over that in the WT group (supplementary Table 2, Figure 5). Only IL-6 was significantly lower in the WT ulcer group than that in the WT control group (supplementary Table 2, Figure 5).

Discussion

Recent studies have described the indispensable contribution of HGF to suppress inflammation in wound healing [13,28]. However, the expression pattern of HGF in inflammatory oral mucosa ulcers is still unknown. In this study, we detected upregulation of HGF protein in the oral traumatic ulcer tissue of mice compared with healthy oral mucosa. Our results also indicated the higher expression of HGF in saliva during oral traumatic ulceration in humans. At the same time, oral traumatic ulcer conditions increased the level of serum HGF in WT mice. Although oral ulcer is an

oral mucosa disease, the inflammatory nature of the disease makes it relevant to various systemic effects, including body weight and quality of life [5,29]. These results suggest the possible role of increased HGF on the systemic effects of oral traumatic ulcers.

Moreover, high HGF expression has been shown to mediate anti-inflammatory action and regeneration in a variety of inflammatory and traumatic models, including oral tissues [14,30-34]. HGF is upregulated in injured tissues or organs, probably due to the need for tissue repair and anti-inflammation toward immune cells [7]. In this study, we found that upregulated HGF inhibited the clinical process and tissue inflammatory reactions of ulcers. This finding was confirmed by histological observations, which showed a decreased ulcer score and inflammatory cells in HGF-Tg mice, suggesting the possible role of HGF in alleviating inflammation and improving wound healing in oral traumatic ulcers.

Ulceration in the oral cavity can cause weight loss in animal models, which is probably due to high infection, the slow healing process and large ulcer area [1]. HGF gene therapy has been reported to decrease the size of ulcers in patients with critical limb ischemia [23]. Yuge et al. showed that HGF gene therapy prevented weight loss in sulfate-induced colitis in mice [35]. Additionally, HGF mice improved body regain after subcutaneous transplantation of diabetic rats [36]. Our results also showed that the ulcer area and ulcer-induced weight loss were significantly lower in HGF-Tg mice. This therapeutic effect of HGF is probably associated with increased epithelial proliferation, an anti-inflammatory effect, and a reduction in the number of infiltrating immune cells [13,19,35,37,38].

Our findings indicated that the effect of HGF on the healing of oral wounds involves decreasing the number of neutrophils in connective tissue of wound sites as well as circulating neutrophils. Neutrophils are the major infiltrating cells in wounds, especially in the early phase of damage [39]. One study has shown that HGF-specific c-Met knockout mice show significantly severe neutrophil infiltration in nonalcoholic fatty liver disease (NAFLD) [40]. HGF treatment can decrease the lymphocytes of the spleen in a mouse model [20]. In contrast, Bevan et al. reported that HGF/SF strongly improved skin wound repair in *db/db* mice by recruiting immune cells to the site of the wound through the repair process [41]. We also found that circulating T cells were

higher in HGF-Tg mice. Thus, HGF mediates different immune reactions in different disease models and different stages of the same disease, and these dynamic changes have improved the understanding of HGF-mediated anti-inflammation.

The systemic inflammatory process is indispensable for the healing of oral ulcers, and severe inflammation may delay the healing of the epithelium [1]. Inflammatory cytokines mediate complex functions in traumatic ulcers, depending on their proportional concentrations [18,41-43]. HGF may be a new drug target to treat metabolic disease by inhibiting inflammatory cytokines in the adipose tissue of HGF-Tg mice [44]. The anti-inflammatory roles of HGF have been described, including inhibiting pro- and inflammatory cytokines, such as TNF- α , IFN- γ , TGF- β and iNOS, increasing anti-inflammatory cytokines, such as RANTES, IL-4, and IL-10, and blocking NF- κ B. All these roles could promote the wound healing process [20,45]. However, some reports have shown that HGF reduced wound damage with higher levels of inflammatory cytokines and lower immune cells [35,46]. This difference can be explained by the selection of different stages of disease for the analysis of immune cell and cytokine expression [35]. We measured the effect of HGF on 40 inflammatory cytokines on the 5th day after the model was established. Almost all cytokines had a higher fold-change of fluorescent signal intensity in the HGF-Tg group than in the WT group, except for fractalkine and MIP-1 alpha. These results are similar to those of previous studies [35,46]. The levels of LIX, IL3, eotaxin, eotaxin-2, MIP-1, BLC, RANTES and MCSF were significantly higher in HGF-Tg mice than in WT mice after injury. Eotaxin, LIX, eotaxin-2, MIP-1, BLC, and RANTES are chemokines that are early signals from traumatic tissues to systemic immune cells [42]. This suggests that HGF promotes a stronger signal for the recruitment of inflammatory cells into traumatic tissue in the early stages of inflammation [35,42]. The levels of the colony-stimulating factors, LIX and IL3, were also significantly higher in the HGF-Tg mice, possibly suggesting better tissue recovery after injury [42]. We also observed that almost all the pro- and anti-inflammatory cytokines increased in HGF-Tg mice, although the difference showed no statistical significance. Therefore, HGF can contribute to anti-inflammatory effects and wound repair by adjusting cytokine production [8].

In this study, we revealed a higher expression of HGF in the clinical saliva of oral traumatic ulceration patients. We further detected higher HGF expression in the

ulcer tissue and serum of mice with traumatic ulcers of the oral mucosa. This result suggests HGF as a possible diagnostic marker of oral ulcers. The HGF-Tg ulcer mouse model unveiled the role of HGF in the prevention of neutrophils. The healing process of wounds is a complex, programmed event of genetic and biological series, and HGF is one of the potential growth factors that participate in the whole process of wound healing [47]. A limitation of this study is that we did not analyze the role of HGF in the re-epithelialization of wounds. Reepithelialization is important for ulcer healing, and HGF can promote skin and corneal wound healing by promoting the migration and proliferation of keratinocytes in the epithelium in an inflammatory environment [13,48]. Another limitation of this study is that we did not analyze the mechanism of HGF-mediated anti-inflammation during the ulcer healing process. Our ongoing study will investigate the precise mechanism of HGF in the repair process of oral ulcers.

In conclusion, we observed that HGF-Tg ulcer mice had less weight loss and ulcer area, less Ly6G-positive neutrophil infiltration, and higher levels of circulating cytokines, with a positive effect on the healing of oral traumatic ulcers.

Ethics statement

This animal experimentation was approved by the ethics committee of Affiliated Stomatology Hospital of Guangzhou Medical University (date of approval: 2016.2.26, approval number: 2016-067), and written informed consent was obtained from all patients and controls.

Funding

This study was supported by the Health Department of Guangdong Province, China [grant number A2019200].

Conflicts of interest

All authors declare no conflicts of interest.

Author Contributions

Xinhong Wang designed and collected data and wrote the manuscript. Liting Yan performed the experiments and wrote the paper. Yinghua Tang, Xiaoxi He, Zhao Xiaomin, Liu Weijia and Wu Zhicong performed the experiments and analyzed the results. Gang Luo designed and conceived the study.

Acknowledgments: We thank Changbao Huo for HE and immunohistochemical staining support.

References:

- 1- Silva PBG, Codes ÉBB, Freitas MO, Martins JOL, AlvesAPNN, Sousa FB. Experimental model of oral ulcer in mice: Comparing wound healing in three immunologically distinct animal lines. *J Oral Maxillofac Pathol.* 2018;22(3):444.
- 2- Silva PGB, Jde SN, Brizeno A, Ferreira JM, Sousa FB, Mota MR, Alves AP. TNF-alpha expression, evaluation of collagen, and TUNEL of *Matricaria recutita* L. extract and triamcinolone on oral ulcer in diabetic rats. *J Appl Oral Sci.* 2016;24(3): 278-90.
- 3- Fitzpatrick SG, Cohen DM, Clark AN. Ulcerated Lesions of the Oral Mucosa: Clinical and Histologic Review. *Head Neck Pathol.* 2019;13(1):91-102.
- 4- Hanson SE, Bentz ML, Hematti P. Mesenchymal stem cell therapy for nonhealing cutaneous wounds. *Plast Reconstr Surg.* 2010;125(2):510-6.
- 5- Cavalcante GM, Paula RGS, Souza LP, Sousa FB, Mota MRL, Alves APNN. Experimental model of traumatic ulcer in the cheek mucosa of rats. *Acta Cir Bras.* 2011;26(3):227-34.
- 6- Mesquita KC, Dantas TS, de Barros Silva PG, de Queiroz Rodrigues MI, Alves APNN, Mota MRL, et al. Abatacept treatment impairs the cell migration and wound healing of oral ulcers in rats: Role of interleukin (IL)-1 β , -6 and -10 and CD8/CD30 cells: Influence of abatacept treatment on oral wound healing: Experimental model on rats. *Life Sci.* 2020;243:117243.
- 7- Nakamura T, Mizuno S. The discovery of hepatocyte growth factor (HGF) and its significance for cell biology, life sciences and clinical medicine. *Proc Jpn Acad Ser B Phys Biol Sci.* 2010;86(6):588-610.
- 8- Ilangumaran S, Villalobos-Hernandez A, Bobbala D, Ramanathan S. The hepatocyte growth factor (HGF)-MET receptor tyrosine kinase signaling pathway: Diverse roles in modulating immune cell functions. *Cytokine.* 2016;82: 125-39.

381 9-Miyagi H, Thomasy SM, Russell P, Murphy CJ. The role of hepatocyte growth
 382 factor in corneal wound healing, *Exp Eye Res*, 2018 Jan; 166:49-55.

383 10- Gallo S, Sala V, Gatti S, Crepaldi, T. Cellular and molecular mechanisms of
 384 HGF/Met in the cardiovascular system. *Clin Sci (Lond)*. 2015; 129(12):1173-93.

385 11- Bendinelli P, Matteucci E, Dogliotti G, Corsi MM, Banfi G, Maroni P, et al.
 386 Molecular basis of anti-inflammatory action of platelet-rich plasma on human
 387 chondrocytes: mechanisms of NF- κ B inhibition via HGF. *J Cell Physiol*. 2010;
 388 225(3):757-66.

389 12- Rong SL, Wang XL, Wang YC, Wu H, Zhou XD, Wang ZK, et al. Anti-inflammatory
 390 activities of hepatocyte growth factor in post-ischemic heart failure. *Acta Pharmacol*
 391 *Sin*. 2018; 39(10):1613-21.

392 13- Omoto M, Suri K, Amouzegar A, Li M, Kishore R, Katikireddy MR, et al.
 393 Hepatocyte Growth Factor Suppresses Inflammation and Promotes Epithelium Repair
 394 in Corneal Injury. *Mol Ther*. 2017; 25(8):1881-8.

395 14- Ishibashi H, Tonomura H, Ikeda T, Nagae M, Sakata M, Fujiwara H, et al.
 396 Hepatocyte growth factor/c-Met promotes proliferation, suppresses apoptosis, and
 397 improves matrix metabolism in rabbit nucleus pulposus cells in vitro. *J Orthop Res*.
 398 2016; 34(4):709-16.

399 15- Imamura H, Mstsumoto RK. Hepatocyte growth factor in physiology and
 400 infectious diseases. *Cytokine*. 2017; 98: 97-106.

401 16- Sanada F, Fujikawa T, Shibata K, Taniyama Y, Rakugi H, Morishita
 402 R. Therapeutic angiogenesis using HGF plasmid. *Ann Vasc Dis*. 2020; 13(2):109-15.

403 17- Baek JH, Birchmeier C, Zenke M, Hieronymus T. The HGF receptor/Met tyrosine
 404 kinase is a key regulator of dendritic cell migration in skin immunity. *J Immunol*.
 405 2012; 189(4):1699-707.

406 18- Bai L, Lennon AI, Caplan DP, DeChant A, Hecker J, Kranso J, et al. Hepatocyte
 407 growth factor mediates mesenchymal stem cell-induced recovery in multiple sclerosis
 408 models. *Nat Neurosci*. 2012; 15(6):862-70.

409 19- Pang Y, Liang MT, Gong Y, Yang Y, Bu PL, Zhang M, et al. HGF Reduces
410 Disease Severity and Inflammation by Attenuating the NF-kappaB Signaling in a Rat
411 Model of Pulmonary Artery Hypertension. *Inflammation*. 2018;41(3):924-31.

412 20- Cao XP, Han DM, Zhao L, Guo ZK, Xiao FJ, Zhang YK, et al. Hepatocyte growth
413 factor enhances the inflammation-alleviating effect of umbilical cord-derived
414 mesenchymal stromal cells in a bronchiolitis obliterans model. *Cytotherapy*. 2016;
415 18(3):402-12.

416 21- Li JF, Duan HF, Wu CT, Zhang DJ, Deng Y, Yin HL, et al. HGF accelerates
417 wound healing by promoting the dedifferentiation of epidermal cells through β 1-
418 integrin/ILK pathway. *Biomed Res Int*. 2013;470418.

419 22- Hisadome M, Ohnishi T, Kakimoto K, Kusuyama J, Bandow K, Kanekura T, et
420 al. Hepatocyte growth factor reduces CXCL10 expression in keratinocytes. *FEBS*
421 *Lett*. 2016;590(20):3595-3605.

422 23- Morishita R, Shimamura M, Takeya Y, Nakagami H, Chujo M, Ishihama T, et
423 al. combined analysis of clinical data on HGF gene therapy to treat critical limb
424 ischemia in japan. *Curr Gene The*. 2020;20(1):25-35.

425 24- Powell RJ, Simons M, Mendelsohn FO, Daniel G, Henry TD, Koga M, et al.
426 Results of a Double-Blind, Placebo-Controlled Study to Assess the Safety of
427 Intramuscular Injection of Hepatocyte Growth Factor Plasmid to Improve Limb
428 Perfusion in Patients With Critical Limb Ischemia. *Circulation*. 2008;118(1): 58-65.

429 25- Dally J, Khan JS, Voisey A, Charalambous C, John HL, Woods EL, et al.
430 Hepatocyte growth factor mediates enhanced wound healing responses and resistance
431 to transforming growth factor- β 1-driven myofibroblast differentiation in oral mucosal
432 fibroblasts. *Int J Mol Sci*. 2017;18(9):1843-57.

433 26- Wang X, Tang Y, Shen R, Chen J, Chen G, Luo G, et al. Hepatocyte growth
434 factor (HGF) optimizes oral traumatic ulcer healing of mice by reducing
435 inflammation. *cytokine*. 2017; 99: 275-80.

436 27- Ng YL, Klopčič B, Lloyd F, Forrest C, Greene W, Lawrance IC. Secreted protein
437 acidic and rich in cysteine (SPARC) exacerbates colonic inflammatory symptoms in
438 dextran sodium sulphate-induced murine colitis. *PLoS One*. 2013;8(10):e77575.

439 28- Song P, Han T, Xiang X, Wang Y, Fang H, Niu Y, et al. The role of hepatocyte
440 growth factor in mesenchymal stem cell-induced recovery in spinal cord injured rats.
441 Stem Cell Res Ther. 2020;11(1): 178-92.

442 29- Mays JW, Sarmadi M, Moutsopoulos NM. Oral Manifestations of Systemic
443 Autoimmune and Inflammatory Diseases: Diagnosis and Clinical Management. J Evid
444 Based Dent Pract. 2012;12(3 Suppl):265-82.

445 30- Sorour AE, Lönn J, Nakka SS, Nayeri T, Nayeri F. Evaluation of hepatocyte
446 growth factor as a local acute phase response marker in the bowel: the clinical impact
447 of a rapid diagnostic test for immediate identification of acute bowel inflammation.
448 Cytokine. 2015;71: 8-15.

449 31- Avetisyan M, Wang H, Schill EM, Bery S, Grider JR, Hassell JA, et al.
450 Hepatocyte Growth Factor and MET Support Mouse Enteric Nervous System
451 Development, the Peristaltic Response, and Intestinal Epithelial Proliferation in
452 Response to Injury. J Neurosci. 2015;35(33): 11543-58.

453 32- Boldyreva MA, Bondar IV, Stafeev IS, Makarevich PI, Beloglazova IB, Zubkova
454 ES, et al. Plasmid-based gene therapy with hepatocyte growth factor stimulates
455 peripheral nerve regeneration after traumatic injury. Biomed Pharmacother. 2018;101:
456 682-90.

457 33- Guru S, Sam SE, Rajan S, Padmanabhan S. Comparative evaluation of salivary
458 hepatocyte growth factor in smokers and non-smokers with chronic periodontitis. J
459 Investig Clin Dent. 2018;9(2):e12306.

460 34- Ohnishi T, Suwa M, Oyama T, Arakaki N, Torii M, Daikuhara Y. Prostaglandin
461 E2 predominantly induces production of hepatocyte growth factor/scatter factor in
462 human dental pulp in acute inflammation. J Dent Res. 2000;79(2):748-55.

463 35- Yuge K, Takahashi T, Khai NC, Goto K, Fujiwara T, Fujiwara H, et al.
464 Intramuscular injection of adenoviral hepatocyte growth factor at a distal site
465 ameliorates dextran sodium sulfate-induced colitis in mice. Int J Mol Med.
466 2014;33(5):1064-74.

467 36- Yang SY, Yang KC, Sumi S. Prevascularization-free Primary Subcutaneous
468 Transplantation of Xenogeneic Islets Coencapsulated With Hepatocyte Growth
469 Factor. *Transplant Direct*. 2020;6(11): e620.

470 37- Li JF, Duan HF, Wu CT, Zhang DJ, Youping Deng YP, Yin HL, et al. HGF
471 Accelerates Wound Healing by Promoting the Dedifferentiation of Epidermal Cells
472 through 1-Integrin/ILK Pathway. *Biomed Res Int* Actions Search in PubMed Search in
473 NLM Catalog Add to Search. 2013; 2013:470418.

474 38- Lu Z, Chang W, Meng S, Xu X, Xie J, Guo F, et al. Mesenchymal stem cells
475 induce dendritic cell immune tolerance via paracrine hepatocyte growth factor to
476 alleviate acute lung injury. *Stem Cell Res Ther*. 2019;10(1): 372-97.

477 39- Ahlfors E, Czerkinsky C. Contact sensitivity in the murine oral mucosa. I. An
478 experimental model of delayed-type hypersensitivity reactions at mucosal surfaces.
479 *Clin Exp Immunol*. 1991;86(3):449-56.

480 40- Kroy DC, Schumacher F, Ramadori P, Hatting M, Bergheim I, Gassler N, et al.
481 Hepatocyte specific deletion of c-Met leads to the development of severe non-
482 alcoholic steatohepatitis in mice. *J Hepatol*. 2014;61(4):883-90.

483 41- Bevan D, Gherardi E, Fan TP, Edwards D, Warn R. Diverse and potent activities
484 of HGF/SF in skin wound repair, *J Pathol*. 2004; 203(3):831-8.

485 42- Clausen JF, Clausen F, Marklund N, Hillered L. Acute inflammatory biomarker
486 responses to diffuse traumatic brain injury in the rat monitored by a novel
487 microdialysis technique. *J Neurotrauma*. 2019;36(2):201-11.

488 43- Hutchinson PJ, O'Connell MT, Rothwell NJ, Hopkins SJ, Nortje J, Carpenter K, et
489 al. Inflammation in human brain injury: intracerebral concentrations of IL-1alpha, IL-
490 1beta, and their endogenous inhibitor IL-1ra. *J Neurotrauma*. 2007;24(10):1545-57.

491 44- Muratsu J, Iwabayashi M, Sanada F, Taniyama Y, Otsu R, Rakugi H, et al.
492 Hepatocyte growth factor prevented high-fat diet-induced obesity and improved
493 insulin resistance in mice. *Sci Rep*. 2017; 7:130-36.

494 45- Benkhoucha M, Santiago-Raber M, Schneider G, Chofflon M, Funakoshi H,
495 Nakamura T, et al. Hepatocyte growth factor inhibits CNS autoimmunity by inducing

496 tolerogenic dendritic cells and CD25⁺Foxp3⁺ regulatory T cells. *Proc Natl Acad*
497 *Sci U S A*. 2010;107(14): 6424-29.

498 46- Jeschke MG, Bolder U, Finnerty CC, Przkora R, Müller U, Maihöfer R, et al. The
499 effect of hepatocyte growth factor on gut mucosal apoptosis and proliferation, and
500 cellular mediators after severe trauma. *Surgery*. 2005 ;138(3):482-9.

501 47- Valente S, Ciavarella C, Pisanisi E, Ricci F, Stella A, Pasquinelli G. Hepatocyte
502 growth factor effects on mesenchymal stem cells derived from human arteries: a novel
503 strategy to accelerate vascular ulcer wound healing. *Stem Cells Int*. 2016;(2016):3232
504 859.

505 48- Miura Y, Bich VNT, Furuya M, Hasegawa H, Takahashi S, Katagiri N, et al. The
506 small G protein Arf6 expressed in keratinocytes by HGF stimulation is a regulator for
507 skin wound healing. *Sci Rep*. 2017;7: 46649.

508

509 Supplementary Table 1- Clinical characteristics and demographics of the 17 healthy
510 controls, 18 OTU patients and 13 RAS patients included in this study.

511

512 Supplementary Table 2- Mean cytokine concentrations (pg/ml) with standard error of the
513 mean on the 5th day.

514

515 Figure 1- Ulcer-induced HGF alleviates ulcer area and weight loss in mice.

516 Expression of HGF in (A) saliva of OTUs (n=18), RAS patients (n=14) and healthy
517 individuals (n=17) and (B) mucosal tissue in healthy and ulcerated WT or HGF-Tg
518 mice (n=7). (C) Serum level of HGF protein in healthy and ulcerated WT or HGF-Tg
519 mice (n=5). (D) Ulcer area of the buccal mucosa in WT and HGF-Tg mice, and (E)
520 quantitative data for the ulcer area analyzed from macroscopic observation on the 3rd
521 day (n=12) and the 5th day (n=18). (F) Weight loss of WT and HGF-Tg mice (n=34).
522 Significant differences among the groups, *p<0.05, ** p<0.01, ***p<0.001.

523 Figure 2- HGF overexpression alleviates inflammation of ulcer tissues on the 5th day.

524 (A) HE-stained histological images of ulcers in the WT and HGF-Tg mice. (B)
525 Quantitative data of the histological scores from HE staining (n=18). Representative
526 immunohistochemical staining of CD45 (C) and Ly6G (E) in ulcer sections. (D)
527 Quantitative data of CD45 from immunohistochemical staining. (F) Quantitative data
528 of Ly6G from immunohistochemical staining. The difference significance among the
529 groups, *p<0.05.

530 Figure 3- HGF overexpression alleviates serum neutrophils and ulcer T cells on the 5th
531 day. Inflammatory cells were isolated from the blood of the WT (n=10) and HGF-Tg
532 mice (n=10) and stained for Ly6G (A), CD19 (C), CD3 (E) and CD4/CD8 (G).
533 Quantitative data for Ly6G (B), CD19 (D), CD3 (F) and CD4/CD8 (H). Significant
534 differences among the groups, *p<0.05, ***p<0.001.

535 Figure 4- HGF overexpression alleviates ulcer tissue neutrophils. Inflammatory cells
536 on the 5th day. Inflammatory cells were isolated from the ulcer tissue of the WT (n=8)

and HGF-Tg mice (n=7) and stained for Ly6G (A), (B) Quantitative data for tissue Ly6G. Significant differences among the groups, ** p<0.01.

Figure 5- HGF overexpression triggers upregulation of blood inflammatory factors on the 5th day. (A) Representative images of antibody arrays against 39 cytokines. (B) Significantly increased concentrations of serum inflammatory factors. Significant differences among the groups, *p<0.05, ** p<0.01.

544

545

Supplementary Table 1- Clinical characteristics and demographics of the 17 healthy controls, 18 OTU patients and 14 RAS patients included in this study.

Gender	Age	RAS
Female	55	-
Female	26	-
Female	22	-
Female	22	-
Female	24	-
Female	33	-
Male	33	-
Female	29	-
Female	29	-
Male	27	-

Male	56	-
Female	36	-
Female	27	-
Female	24	-
Male	24	-
Female	45	-
Female	41	-
Male	37	TU
Female	54	TU
Male	35	TU
Female	26	TU
Female	22	TU
Male	27	TU
Female	35	TU
Male	59	TU
Male	39	TU
Male	31	TU
Female	49	TU
Female	37	TU
Male	25	TU
Female	23	TU
Male	19	TU
Female	64	TU
Female	68	TU

Male	48	TU
Male	26	MiRAS
Male	31	MiRAS
Male	56	MiRAS
Male	22	MiRAS
Female	67	MiRAS
Male	44	MiRAS
Male	34	MiRAS
Male	22	MaRAS
Female	33	MiRAS
Male	39	MiRAS
Male	51	MiRAS
Female	50	MaRAS
Female	45	MaRAS
Female	30	MaRAS

550

 MiRAS: Minor recurrent stomatitis; MaRAS: major recurrent stomatitis

551

552 Supplementary Table 2- Mean cytokine concentrations (pg/ml) with standard error of the

553 mean.

cytokine	Fold change					
	Control mean±SD	WT-ulcer mean±SD	HGF-ulcer mean±SD	WTulcer vs WT	HGF ulcer vs WT	HGF ulcer vs WT ulcer
BLC	1201.2±207.6	1200.6±440.3	4467.4±3404.3	1	3.72**	3.72***

CD30L	1453.8±287.3	2064.4±1729.1	3901.1±6808.1	1.42	2.68	1.89
Eotaxin	21527.1±381.3	25125.0±4256.8	51258.6±15606.5	1.17	2.38**	2.04***
Eotaxin-2	13929.9±3749.2	16765.8±3457	28012.3±11211.4	1.2	2.01	1.67***
Fas ligand	396.8±131.6	392.5±115.7	4512.3±5085.1	0.99	11.37	11.5
Fractalkine	730.7±186.9	538.6±194.8	537.5±285.5	0.74	0.74	0.99
GCSF	912±266.2	929.7±331.1	12558.1±22967.8	1.02	13.77	13.51
GM-CSF	2594.5±507.3	2810.6±801	10378±6320.5	1.08	2.44	2.25
IFN-gamma	3001.7±146.5	3492±1121.3	7697.9±9176.9	1.16	2.57	2.20
IL-1 alpha	876.7±378.3	680±304.2	1054.7±648.1	0.78	1.2	1.55
IL-1 beta	631.2±261.7	570±152.6	4114±4541.5	0.90	6.52	7.22
IL10	2779±824.9	3526.5±2292.4	5550.3±8044.8	1.27	1.99	1.57
IL-12p40/p70	2450.5±755.2	3106.4±1673.7	7574.7±811.4	1.27	3.09	2.44
IL-12p70	2675.7±279.8	3038.2±680.5	5664.3±6470.1	1.14	2.12	1.86
IL-13	2218±435.8	2978.5±1516.6	9679.1±11064.7	1.34	4.36	3.25
IL-17	2270.1±228.9	2608±873.3	11182.7±6317.2	1.15	2.78	2.42
IL2	1517±160.5	1997.8±764.5	9589.5±17513.3	1.32	6.32	4.8
IL3	2604.4±636.2	2886.2±1639.9	13858±12876.3	1.11	5.32**	4.8***
IL4	2512.4±281.7	2775.6±377	6339.1±9660.8	1.11	2.52	2.28
IL6	804.9±251.2	436.6±178.4	492.2±282.2	0.54*	0.61	1.12
IL9	3117.1±462.2	4279.2±2336.8	5876.7±5637.1	1.37	1.89	1.37
I-TAC	352±150.4	330.6±183.3	329.4±180.2	0.94	0.94	1
KC	600.1±220	499.5±253.1	580.6±338.8	0.83	0.97	1.16
Leptin	298.2±92	289.9±136.3	505.8±269.4	0.97	1.69	1.74
LIX	13199.1±4719.1	15823.3±5557.3	25329.7±7926	1.19	1.92**	1.6***
Lymphotactin	1259.3±85.8	1617.7±614.6	2534.8±2865	1.28	2.01	1.56
MCP-1	2346.2±302	2487.9±498.6	1364.9±13504.8	1.06	4.42	4.17
MCSF	351.1±167.6	686.7±286	1020.1±433.3	1.96	2.91**	1.49
MIG	542.1±102.2	836±275.1	1380.3±627.6	1.54	2.55	1.65
MIP-1 alpha	664.5±372.3	548.3±112.9	483.8±346.5	0.83	0.73	0.88
MIP-1 gamma	16683.6±6245.7	172908±9376.2	236130.4±52249.1	1.04	1.42**	1.36***
RANTES	640.4±197.8	514±85.8	3890.8±3745.2	0.80	6.08**	7.57***

SDF-1	461.2±214.1	373.3±149	749.5±415.7	0.81	1.63	2.01
sTNF RI	3774.8±999.1	3070.3±826.6	3708.4±1348.8	0.81	0.98	1.21
sTNF RII	1609.2±22.6	2097.4±658.7	3452.2±3601.6	1.3	2.15	1.65
TCA-3	1521.8±529	2548.4±509.5	3820.9±1580.6	1.68*	2.51**	1.50
TECK	433.9±119.6	445.4±97.5	553.9±326.8	1.03	1.28	1.25
TIMP-1	2077.9±317	2196.5±327.4	12400.3±17114.6	1.06	5.97	5.65
TIMP-2	184371.8±19139.9	216848.1±60565.1	286402.6±113626.4	1.18	1.58	1.32

554

555 * indicates significantly higher concentrations in WT ulcers than in the control group
556 (p<0.05); ** indicates significantly higher concentrations in HGF ulcers than in the
557 control animals (p<0.05). *** indicates significantly higher concentrations in HGF ulcers
558 than in WT ulcers (p<0.01).

559

560

561